Purpose: To evaluate IL13Ra2 as an immunotherapeutic target for eliminating glioma stem-like cancer initiating cells (GSC) of high-grade gliomas, with particular focus on the potential of genetically engineered IL13Ra2-specific primary human CD8
Introduction
The prognosis of patients with high-grade gliomas remains grim despite improvements in standard therapies including surgery, radiation, and chemotherapy. The deadly nature of this disease is, in part, attributed to therapeutically resistant subpopulations of glioma stem-like cancer-initiating cells (GSC) that display many characteristics of normal stem cells, including expression of stem cell markers and the potential for sustained self-renewal (1, 2) . GSCs exhibit potent tumor-initiating potential and are hypothesized to seed disease recurrence (3) (4) (5) because of their resistance to conventional chemotherapy and radiation regimens.
Cellular immunotherapies have the potential to target and eliminate this therapeutically resistant GSC population (6) . Recent promising data have shown that tumor stem cells are susceptible to both CTL and natural killer perforindependent killing mechanisms (7) (8) (9) (10) (11) . Furthermore, GSCs and differentiated tumor cells express equivalent levels of markers involved in immunologic synapse formation, and CD8
þ CTL can eliminate cell populations capable of tumor engraftment (9) . Although challenges remain in addressing the confounding effects of tumor immunosuppressive networks, particularly as they relate to specific strategies that may be employed by tumor stem cells (12) (13) (14) , the intrinsic ability of immune cells to recognize and kill tumor stem cells is sufficiently powerful to warrant efforts to overcome these obstacles. IL-13 receptor a2 (IL13Ra2) is a cell-surface receptor that has received significant attention from brain tumor therapy because it is overexpressed by a subset of high-grade gliomas, but not expressed at significant levels by normal brain tissue (15) (16) (17) (18) . Our group has developed an IL13Ra2-targeting immunotherapy platform for high-grade gliomas by genetically modifying T cells to express an IL13Ra2-specific chimeric antigen receptor (CAR) termed IL13-zetakine (19) . This CAR recognizes IL13Ra2 via a membranetethered IL13 ligand and initiates cytolytic killing via an intracellular CD3-zeta T-cell activating domain. It also incorporates a point mutation in the IL13 ligand domain (E13Y) for preferential binding to IL13Ra2 and reduced affinity to the more ubiquitously expressed IL13 receptor, IL13Ra1 (20) . Previous studies using U87 and other longestablished cell lines show that engineered IL13-zetakine þ T cells exhibit potent MHC-independent, IL13Ra2-specific anti-glioma cytolytic activity, and induce regression of orthotopic xenografts in vivo (19) . Realization of the potential of therapies targeting IL13Ra2 for the treatment of malignant glioma, some of which are in clinical trial (21) (22) (23) (24) , will hinge, in part, on their ability to eradicate malignant stem/initiating tumor cell subpopulations. Here we assess the expression of IL13Ra2 on stem-like versus differentiated glioma populations and evaluate the relative susceptibility of glioma cell populations of varying differentiation status to IL13-zetakine þ CTL-mediated killing.
Materials and Methods

Cell lines
Glioma specimens, graded according to World Health Organization-established guidelines (Supplementary  Table S1 ), were obtained from patients in accordance with Institutional Review Board (IRB)-approved protocols. Tumor specimens were deidentified and given unique patient brain tumor (PBT) numbers. For one tumor obtained from a patient who participated in our adoptive T-cell therapy clinical trial, it was also referred to by its unique patient number (UPN) to indicate the patient from whom this tumor was derived (PBT015-UPN033). Shortterm tumor sphere (TS) cultures of GSCs and adherent lines were expanded and cultured as previously described (9) . In some cases tumor explants were expanded by heterotopic subcutaneous passaging in mice before growth and characterization in culture (9) , and in such cases the subcutaneous passage number is reported after the PBT number (for instance, PBT009-2 was subcutaneously passaged twice, and PBT003-4 and PBT017-4 were subcutaneously passaged 4 times). Differentiated lines (DIF) were generated by growing TSs in Sato's Media [DMEM:F12, 2 mmol/L, L-glutamine, 25 mmol/L HEPES, and 7% fetal calf serum (FCS)] for 7 to 14 days. Adherent lines (ADH) were generated by growing freshly dispersed tumor cells directly in Sato's media and used for assays between passages 7 to 30.
Human peripheral blood mononuclear cells (PBMC) were obtained from healthy donors or patients in accordance with IRB-approved protocols. The generation of IL13-zetakine þ (HD003 IL13-zetakine þ clone 2D7) and
been described previously (19, 25) . CD8 þ T-cell lines derived from a patient who participated in our adoptive T-cell therapy clinical trial is referred to by its UPN designation (UPN033). Healthy donor T cell lines were deidentified and designated unique healthy donor (HD) numbers. T-cell clones were cultured as described (19) , and all assays were carried out between days 10 through 14 of the stimulation cycle. Lymphoblastoid lines (LCL) were established from Epstein-Barr virus-infected human PBMCs (19) . LCL-OKT3 cell lines were engineered to express a membranebound OKT3 single-chain antibody (OKT3scFv) as described previously (26) .
Flow cytometric analysis
Cell-surface expression of IL13Ra2 was detected using goat polyclonal anti-IL13Ra2 (AF146) (R&D Systems), followed by murine anti-goat fluorescein isothiocyanate (Jackson ImmunoResearch) (Supplementary Table S2) . Cell-surface expression of CD133 was detected as described (9) with phycoerythrin (PE)-conjugated mouse anti-human CD133/1 and anti-human CD133/2 (Miltenyi Biotec) (Supplementary Table S2 ). Percent of immunoreactive cells was calculated using the subtraction method via FCS Express version 3 software (De Novo Software).
Western blot analysis
Western blots were probed with goat polyclonal antiIL13Ra2 (AF146) and anti-Olig2 (R&D Systems); rabbit polyclonal anti-Actin (Rockland); and mouse monoclonal anti-b-III Tubulin (Millipore), anti-CD133 (Miltenyi), and anti-GFAP (Sigma-Aldrich) antibodies as per the manufacturers' instructions (Supplementary Table S2 ). Western blots were imaged on the Odyssey Infrared Imaging System (LI-COR), and band intensities were quantified using Odyssey v2.0 software (LI-COR).
Immunofluorescence and immunohistochemistry
TSs were plated on poly-L-ornithine (Sigma) and mouse laminin (BD Biosciences) coated chamber slides to support adherent growth (27) . When required, cells were grown for 7 to 10 days in 10% FCS-containing media to promote astrocytic differentiation (GFAP immunoreactive), or 0.5% FCS with 5 mmol/L forskolin (Sigma) to promote neuronal differentiation (b-III Tubulin immunoreactive). Cells were stained with primary antibodies anti-SOX2 (Abcam), anti-Nestin (Millipore), anti-GFAP (Sigma), and anti-bIII
Translational Relevance
Patient-to-patient heterogeneity of malignant gliomas, together with the presence of the glioma stem-like cancer initiating cells (GSC), thought to be responsible for disease progression and recurrence, have proven to be barriers to disease eradication. In light of these challenges, our study focused on the usefullness of IL13Ra2-directed therapies for targeting the tumorigenic GSC population of high-grade gliomas. Our findings provide evidence that for the subset of patients with IL13Ra2-positive tumors, immune-based therapies targeting IL13Ra2 have the potential to eliminate both the GSCs and bulk differentiated populations.
Tubulin (Millipore) (Supplementary Table S2), followed by anti-mouse or anti-rabbit Alexa-488 (Invitrogen), and costained with 4 0 ,6-diamidino-2-phenylindole (DAPI) mounting solution (Vector Laboratories, Inc.). Cells were visualized using an AX70 fluorescent microscope (Olympus), and exposure settings for each antibody were kept constant between growth conditions. Glioblastoma IL13Ra2 immunohistochemistry (IHC) was done on 5-mm sections of formalin-fixed paraffinembedded specimens, treated with EnVision FLEX Target Retrieval Solution Low pH (Dako) in a PT Link pretreatment module (Dako) for antigen retrieval. Sections were then blocked with serum-free protein block (Dako), incubated with 3.33 mg/mL goat polyclonal anti-IL13Ra2 (AF146), and detected using rabbit anti-goat (Dako) and the EnVision FLEX/HRP system (Dako). All staining was done using the DAKO polymer automated system.
For mouse brain IHC, brains were harvested, fixed and embedded in paraffin as described previously (19) . Horizontal brain sections (10 mm) were deparaffinized, underwent citrate-based antigen retrieval, and stained with antihuman Nestin (Millipore), anti-SOX2 (R&D Systems), antiOlig2 (R&D Systems), or anti-GFAP (Dako) (Supplementary Table S2 ) followed by detection using the EnVision kit (Vector Laboratories) with 50% hematoxylin counterstain.
qPCR
To quantify IL13Ra2 mRNA levels, RNA samples were isolated from cells using the RNeasy Kit (Qiagen), and cDNA was prepared using the Superscript First Strand Synthesis System for reverse transcription PCR (RT-PCR) (Invitrogen). Real-time PCR analysis was done using SybrGreen (Qiagen) with specific primer pairs for IL13Ra2 (GenBank; NM_000640.2) spanning exon 1-2 and exons 6-7 and b-actin (internal PCR control) (Supplementary Table S3 ). Fold-difference in IL13Ra2 mRNA levels compared with the U251T calibrator line was determined using the Livak method (28).
Cytotoxicity and cytokine assays
Chromium release assays (CRA) were carried out as previously described (29) . Cytokine production was measured by coculturing T cells with tumor at a 10:1 effector: target (E:T) ratio. In blocking experiments, anti-IL13 antibody (BD Biosciences) and recombinant human IL-13 (Peprotech) were added at the indicated concentrations to responders and stimulators, respectively, 30 minutes before plating. After 20-to 24-hour incubation, supernatants were harvested and assayed using Luminex multiplex bead technology (Upstate), and output data were analyzed via the Bio-Plex Manager 4.0 (BioRad).
Tumor xenografts and tumor volume determination
Mice were maintained under pathogen-free conditions, and all procedures were done with 6-to 8-week-old nonobese diabetic/severe combined immunodeficient (NODscid) or NOD/scid/IL2R À/À (NSG) mice as approved by the COH Institute Animal Care and Use Committee. Intracranial tumor xenografts were prepared as previously described (19) . No difference in tumor engraftment between NODscid and NSG mouse strains has been observed. Fixed and paraffin-embedded brains were serially sectioned at 10-mm intervals over the entire extent of the tumor. In most cases, every 20th section was stained with a humanspecific nestin antibody (any human cell will be tumor) and visualized with 3,3 0 -diaminobenzidine (DAB). These sections were scanned at high resolution (Chromavision ACIS II). Brain slice images were aligned and DAB þ pixels in each brain slice were segmented and counted using Reconstruct software (http://synapses.clm.utexas.edu/ tools/reconstruct/reconstruct.stm; ref. 30) . In some cases, segmentation was based on color and cell density in hematoxylin and eosin-stained sections. In all cases pixel area was extrapolated over the 200-mm slice interval and total volumes computed accordingly.
Results
Incidence of glioma-associated IL13Ra2 expression is independent of tumor cell differentiation status Our group has generated a panel of GSC lines from patient glioblastoma specimens grown as TSs in serum-free media supplemented with epidermal growth factor (EGF) and fibroblast growth factor (FGF) (9) . These GSC TS lines were derived either from freshly dispersed human biopsy specimens or after heterotopic subcutaneous passaging of patient biopsy tissue in immunocompromised mice (9, 31) . The expanded GSC TS lines exhibited stem cell-like characteristics: formation of secondary TSs as an indication of in vitro self-renewal potential (Fig. 1A) , expression of stem cell markers such as CD133, SOX2 and Nestin ( . These findings raise questions about previously published reports which used these antibodies, particularly the commonly used anti-IL13Ra2 B-D13 antibody (Cell Sciences), to assess the frequency of IL13Ra2 expression on gliomas (18, 33) . This inconsistency may also underlie the lack of correlation between IL13Ra2 mRNA and protein expression for primary glioma biopsy specimens when the anti-IL13Ra2 B-D13 antibody (Cell Sciences) was used for IHC (34) . We have therefore used the goat polyclonal anti-IL13Ra2 AF146 antibody (R&D Systems) for all experiments, as it is the only antibody tested that shows a consistent correlation between IL13Ra2 protein levels and mRNA expression [Western and flow cytometry vs. qRT-PCR; Fig. 2A -C, and Supplementary Fig. S1 ].
We next evaluated IL13Ra2 on stem-like TS lines and found that expression was highly variable between tumor specimens, with a subset of TSs (i.e., PBT015-UPN033, PBT017-4, and PBT030) expressing significant levels of IL13Ra2 (>70% positive by flow cytometry), and approximately half of the tumor lines (i.e., PBT003-4, PBT008, and PBT009-2) not expressing detectable levels of this receptor by either flow cytometry or Western blot ( Fig. 2D and E) . IL13Ra2 transcript levels, as measured by qRT-PCR, correlated with the observed IL13Ra2 protein expression (Fig.  2C ). Our observations are thus in agreement with previous studies showing that the IL13Ra2 receptor is expressed by a subset of patient glioblastoma tumor samples (16, 34) .
An expanded normal fetal brain neural stem cell line did not express IL13Ra2 as assessed by flow cytometry and qRT-PCR ( Fig. 2C and D) . This observation suggested that the IL13Ra2 receptor is not expressed by normal neural stem cells and is in concordance with previous reports that this receptor is not expressed at significant levels in normal brain tissue (15) (16) (17) 35) .
Significantly, we found that IL13Ra2 is expressed independently of glioma differentiation status. As exemplified by the IL13Ra2 pos lines (PBT015-UPN033, PBT017-4, and PBT030), receptor expression is maintained on the stemlike TS (CD133 pos Olig2 pos ), the 7-to 14-day serum-differentiated (GFAP pos ; DIF), and the long-term serum-expanded cell populations (ADH; Fig. 2D and E) . A small decrease in IL13Ra2 levels was consistently observed following shortterm differentiation, but not after long-term growth in serum-containing media (comparing DIF vs. ADH), possibly due to the withdrawal of EGF mitogen (36) . Reciprocally, IL13Ra2 neg primary lines (PBT003-4, PBT008, and PBT009-2) do not upregulate IL13Ra2 neg upon differentiation and growth in serum-containing media ( Fig. 2D and E). We concluded that although IL13Ra2 expression by high-grade gliomas is heterogeneous between different tumor samples, its expression on any given low-passage glioma line is independent of cell differentiation status. Thus, these data suggested that, for gliomas expressing IL13Ra2, therapeutic strategies targeting this receptor could potentially eliminate the stem-like brain tumor subpopulation. These studies also indicated the presence of glioma stem-like tumor-initiating populations that do not express IL13Ra2, as detected for the IL13Ra2 neg tumors. To assess the extent to which expression of IL13Ra2 on expanded primary cell lines correlates with the originating patient tumor, IL13Ra2 IHC was done on paraffin-embedded patient tumor tissue. As shown in Fig. 3 , patient tumors with the highest overall IL13Ra2 expression levels (!40% of cells positive) as detected by IHC (PBT015-UPN033, PBT017, and PBT030), generated both TS and DIF/ADH lines with correspondingly high IL13Ra2 expression (compare with Fig. 2D and E) . Likewise, patient tumors with low IL13Ra2 levels ( 20% positive cells) gave rise to cell lines that lacked receptor expression (PBT008 and PBT009). Importantly, these findings indicated that expression levels of IL13Ra2 on expanded primary glioma cell lines are consistent with its expression by the originating patient tumor. However, on a cell-by-cell basis, IL13Ra2 expression levels on glioma cells in situ were more variable, as detected by IHC, than those of the corresponding donor-derived TS or ADH cell lines (Fig. 2 vs. Fig. 3 ; refs. 16, 35) . This difference may be explained by the more heterogeneous cellular composition of glioma tumors in situ.
IL13Ra2 expression renders GSCs susceptible to IL13-zetakine-mediated T-cell killing
We next addressed whether IL13Ra2 pos GSCs and differentiated tumor lines display comparable sensitivity to CARengineered CTL-mediated killing. For these studies, primary Fig. S2A and B) were evaluated for their ability to kill TS and matched differentiated glioma lines in vitro. We observed that autologous (UPN033) or allogeneic (HD003) IL13-zetakine þ T-cell clones efficiently lysed IL13Ra2 pos PBT015-UPN033 stem-like TSs, as assessed by chromium-release assay (Fig. 4A) . For both autologous and allogeneic CTLs, TSs were killed at least as well as matched serum-differentiated (DIF) or serum-expanded (ADH) lowpassage primary lines, or established glioma line U87 (average difference in cytotoxicity at all E:T ratios 17% AE 9% with killing of TS ! DIFF/ADH lines). Lymphoblastic (LCL) targets engineered to express the membrane-bound agonistic antibody scFv-OKT3 (LCL-OKT3), which activates T cells via engagement of the CD3 complex, served as a reference target denoting the maximal activation potential of a T-cell line. To establish that the capacity of IL13-zetakine CTLs to target and kill IL13Ra2 pos GSCs is not specific to a particular TS line, we showed in a similar set of experiments that IL13Ra2 pos PBT017-4 and PBT030 TS, DIF, and ADH cells were also recognized and killed independently of differentiation status (Supplementary Fig S3) . In all cases, the stem-like TS lines were killed with comparable potency as the serum-differentiated lines.
PBT015-UPN033
Following engagement of TS, DIF, ADH, or U87 targets, IL13-zetakine þ CTL clones were also activated to produce Tc1 cytokines INF-g and TNF-a (Fig. 4B, Supplementary Fig.  S4 ). CTL coculture with PBT015-UPN033 TSs resulted in slightly less Tc1 cytokine production as compared with serum-differentiated (DIF) cells (average AE SD decrease in INF-g for TS vs. ADH and DIF is 42% AE 7% and 14% AE 2%, respectively; average decrease in TNF-a for TS vs. ADH and DIF is 58% AE 2% and 45% AE 13%, respectively). This decrease in T-cell-mediated INF-g and TNF-a cytokine release is observed on engagement of all IL13Ra2 pos primary glioma lines tested (average 2-to 3-fold decrease) (Supplementary Fig. S4 ).
Several lines of evidence confirmed that the IL13-zetakine þ CTL killing and Tc1 cytokine responses we observed are specific to engagement of IL13Ra2 tumor antigen. First, IL13-zetakine þ CTL clones were not activated for killing or cytokine production when coincubated with the IL13Ra2 neg PBT003-4 TS and T98 glioma lines or the IL13Ra2 neg LCL line (Fig. 4A, B , and D, and data not shown). Second, blocking CAR-IL13Ra2 engagement by either preincubation of PBT015-UPN033 TS targets with recombinant human IL13 (rh-IL13), or IL13-zetakine þ CTL with anti-IL13 antibody eliminated cytokine production (Fig. 4C) . Third, the parental UPN033 bulk CTL line, which is not engineered to express the IL13-zetakine CAR, displayed negligible levels of killing (<10% 51 Cr-release) and cytokine production (<30 pg/mL INF-g and <5 pg/mL TNFa) when challenged with PBT015-UPN033 tumor targets.
These findings confirmed that expression of the IL13Ra2 tumor-associated antigen is necessary for IL13-zetakine þ CTL killing (19) . Importantly our data establishes that both IL13Ra2 pos GSCs and differentiated cells are targeted and killed by IL13-zetakine engineered CTLs, and therefore cells with stem/progenitor-like properties are not intrinsically resistant to CTL-mediated killing.
IL13-zetakine
þ CTL can ablate the tumor-initiating activity of IL13Ra2 pos GSCs in vivo A hallmark characteristic of GSCs is their capacity to initiate in vivo tumor formation at low cell numbers. To address the possibility that a minor tumor-initiating subpopulation of IL13Ra2 pos cells may evade IL13-zetakinemediated recognition, an in vivo tumor engraftment assay was carried out. This assay establishes that capacity of CTL to eliminate glioma tumor-initiating populations (i.e., the functional definition of GSCs), by providing an in vivo read-out of cell populations that resist CTL killing (see Fig. 6 of ref. 9 where antigen-negative tumor populations evaded CTL recognition and initiated tumor). For this study, PBT017-4 TSs were coinjected intracranially into NOD-scid mice with either IL13-zetakine þ CTL, or a nonspecific CTL line expressing a CD19-specific CAR, or PBS. Because as few as 100 PBT017-4 TS cells can initiate highly invasive tumors in NOD-scid mice (9), this assay is expected to detect a minor tumor-initiating population (<0.1%) resistant to IL13-zetakine-mediated CTL killing. We observed that coinjection of IL13-zetakine þ CTL, but not PBS or control CD19R þ CTL, ablated the engraftment potential of PBT017-4 cells (Fig. 5A) . Similarly, IL13-zetakine þ CTL, but not PBS or control CD19R þ CTL, also ablated the tumor-initiating potential of the established glioma cell line U87 grown under differentiating conditions (serum-containing media; Fig. 5B ). As a control for antigen specificity, we showed that IL13-zetakine þ CTL do not ablate the tumor-initiating activity of the IL13Ra2 neg line, PBT003-4 TSs (Fig. 5C) , consistent with the lack of in vitro killing of PBT003-4 when cocultured with IL13-zetakine þ CTL (Fig 4D) . This study showed that IL13-zetakine þ CTL can eliminate the tumor-initiating activity of both IL13Ra2 pos GSCs and differentiated subpopulations.
Regression of established GSC TS-initiated xenografts after adoptive transfer of IL13-zetakine þ T cells
We next evaluated the capacity of IL13-zetakine þ CTL to induce regression of established GSC TS-initiated tumors. For these studies, we examined the antitumor efficacy of IL13-zetakine þ T cells against IL13Ra2 pos GSC TS lines PBT030-2 and PBT017-4 ( Fig. 2 and Supplementary Fig.  S5 ). To facilitate imaging of tumor growth kinetics, PBT030-2 TSs were engineered by lentiviral transduction to express a fusion protein consisting of EGFP and firefly luciferase (ffLuc; EGFP-ffLuc; ref. (Fig. 4) and ablate their tumor-initiating activity (Fig. 5 ). For those mice in which residual tumor was detected following treatment with IL13-zetakine þ CTL, we sought to understand the etiology of tumor escape by evaluating the expression of IL13Ra2 in relationship to stemness (Sox2 and Olig2) and differentiation (GFAP) by IHC (day 15 post final T-cell treatment; day 28 post tumor injection). We found that IL13-zetakine þ CTL-and control CD19R þ CTL-treated tumors express comparable levels of IL13Ra2 (Fig. 6E) , suggesting that residual tumors did not evade therapy due to antigen loss. At this 15-day time point, we were not able to detect any persisting CD3 þ human T cells by IHC (data not shown). Also, we detected comparable levels of SOX2, Olig2, and GFAP (Fig. 6F) , suggesting that there is no major difference in the frequency of stemlike versus differentiated cells in the recurrent tumor following IL13-zetakine þ CTL-mediated tumor targeting.
Although the largest IL13-zetakine þ CTL-treated tumor was found in the leptomeninges (Fig. 6D) , the significance of this engraftment pattern is not clear as this highly invasive PBT017-4 line (Fig. 5 ) is known to engraft at this anatomical site. Taken together, these data indicated that exposure to IL13-zetakine þ CTL has the capacity to reduce tumor growth and tumor burden of established IL13Ra2 expressing tumors. At the same time, these data also suggested that a more potent CAR þ T-cell capable of sustained persistence may be required to completely eliminate all IL13Ra2 expressing tumor cells.
Discussion
Although immunotherapy strategies targeting IL13Ra2 for brain tumors are being clinically pursued (21) (22) (23) (24) , based on its selective expression on malignant versus normal brain tissue (15) (16) (17) (18) , the power of IL13Ra2-directed therapies will depend, in part, on the ability of these approaches to be effective against the highly tumorigenic glioma cancer stem-like population (3, 4) . Our data provide direct evidence that IL13Ra2 expression is not limited to differentiated glioma cells and that IL13Ra2 targeting can potentially eliminate the refractory GSC component of malignant gliomas. We show that GSC TSs derived from IL13Ra2 pos glioma tumors express IL13Ra2 and that its expression renders the IL13Ra2 pos GSC population susceptible to IL13-zetakine þ CAR-engineered T-cell cytolytic lysis.
Importantly, in vitro GSC TSs were killed at equivalent potency as matched differentiated glioma lines. We also show that IL13-zetakine þ CTL ablate the in vivo tumorinitiating activity of IL13Ra2 pos GSCs and, further, mediate robust antitumor activity and limit progression of established IL13Ra2 pos GSC TS-initiated intracranial tumors in mice.
Although our work and others have shown that GSCs are intrinsically susceptible to effector T-cell killing (7, 8, 9) , mechanisms to suppress and/or evade immune function and effector T-cell killing are likely employed by GSCs. Recent studies suggest that GSCs may reduce T-cell activation-dependent proliferation and downmodulate T-cell activation-dependent cytokine production (12, 37) . We also find that GSC TSs are less potent at stimulating IL13-zetakine þ CTLs for antigen-dependent INF-g and TNF-a cytokine production ( Fig. 4; Supplementary Fig S4) . The underlying mechanism of these compromised functionalities and the consequences for antitumor efficacy remain to be resolved. In addition, the malignant stem cell niche is associated with secreted TGF-b and VEGF, as well as activated STAT3, important signals known to inhibit immune responses and thus may protect GSCs in established tumors from efficient T-cell eradication (12, (38) (39) (40) . Despite these hurdles, our findings that CD8 þ CTLs can be engineered to successfully kill the otherwise therapeutically resistant GSC population suggests that efforts to overcome these obstacles are worthwhile. Clinical trials for recurrent high-grade gliomas using IL13-zetakine-redirected CTLs are in early feasibility/safety stages, and although transient tumor regressions have been observed, sustained regressions are still an unrealized outcome (Jensen; unpublished and ref. 24 ). This study focused on the potential barrier of GSCs as a therapeutically resistant reservoir of tumor cells. We provide evidence that disease recurrence following IL13Ra2-directed therapies is not due to the absence of IL13Ra2 expression by all GSC subpopulations, but rather that other mechanisms of escape may also be at play. Furthermore, we show that IL13-zetakine þ CTLs can target and kill IL13Ra2 pos GSCs and regress established GSC-initiated tumors. However, for established tumors, IL13Ra2 expressing glioma populations were not completely eliminated, suggesting that a more powerful Tcell product is needed. To this end, CAR-engineered T-cell lines optimized for T-cell persistence and/or serial tumor killing are under development (26, 41, 42) .
In expressed by other cells in the tumor microenvironment may also enhance the efficacy of clinically targeting this receptor. Importantly, the heterogeneity of IL13Ra2 receptor expression by high-grade gliomas, rather than persistence of refractory GSC populations, is anticipated to be a critical barrier to overcome for clinical responses (Figs. 2 and 3 and refs. 16, 34, 35) . A guiding principle now emerging from a variety of clinical trials suggests that immunotherapeutic approaches targeting single antigens will not be sufficient for durable long-term antitumor responses. Our data showing that IL13Ra2 is expressed by a subset of glioma stemlike-initiating populations susceptible to cell immunotherapy highlight the relevance of translational strategies targeting IL13Ra2 for malignant glioma, particularly when incorporated into combinatorial targeting approaches.
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